Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | UTS2R | Q9UKP6 | 8/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | TGM2 | P21980 | 6/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.36 |
| ▸ | POLB | P06746 | 2/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | TGM6 | O95932 | 1/20 | 0.34 |
| ▸ | F13A1 | P00488 | 1/20 | 0.34 |
| ▸ | TGM1 | P22735 | 1/20 | 0.34 |
| ▸ | PKM | P14618 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6741196 | 0.96 | UTS2R (0.48) | UTS2RNPC1TGM2SMN1; SMN2POLB | |
| SCHEMBL6093947 | 0.86 | SMN1; SMN2 (0.44) | UTS2RTGM2SMN1; SMN2POLBLMNA | |
| SCHEMBL6741280 | 0.86 | UTS2R (0.55) | UTS2RNPC1SMN1; SMN2POLBLMNA | |
| SCHEMBL6093542 | 0.85 | UTS2R (0.37) | UTS2RTGM2SMN1; SMN2GAAKMT2A | |
| SCHEMBL6739733 | 0.82 | UTS2R (0.47) | UTS2RNPC1SMN1; SMN2POLBLMNA | |
| SCHEMBL6741880 | 0.82 | UTS2R (0.44) | UTS2RTGM2SMN1; SMN2POLBLMNA | |
| SCHEMBL6744733 | 0.82 | UTS2R (0.44) | UTS2RTGM2SMN1; SMN2POLBLMNA | |
| SCHEMBL6744780 | 0.80 | UTS2R (0.61) | UTS2R | |
| SCHEMBL6742625 | 0.80 | UTS2R (0.61) | UTS2R | |
| SCHEMBL6741197 | 0.78 | UTS2R (0.52) | UTS2RNPC1SMN1; SMN2POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040152692-A1 | Urotensin antagonist; therapy for congestive heart failure; antiischemic agents; cardiovascular disorders; strokes; hypotensive agents; respiratory system disorders; restenosis; antiinflammatory agents; psychological disorders | SMITHKLINE BEECHAM CORPORATION | 2004-08-05 | — | — | US | claimed |
| US-20040152692-A1 | Urotensin antagonist; therapy for congestive heart failure; antiischemic agents; cardiovascular disorders; strokes; hypotensive agents; respiratory system disorders; restenosis; antiinflammatory agents; psychological disorders | SMITHKLINE BEECHAM CORPORATION | 2004-08-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040152692-A1 | Urotensin antagonist; therapy for congestive heart failure; antiischemic agents; cardiovascular disorders; strokes; hypotensive agents; respiratory system disorders; restenosis; antiinflammatory agents; psychological disorders | UTS2R, PLAUR, SERPINE1 | UTS2R 1/4885NPC1 4334/4885TGM2 730/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.